How Ph.D. was paid
$6.1M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Vipin K. Garg, Ph.D.Chief Executive Officer | $633,360 | $1,560,896 | $3,536,567 | $330,931 | $28,708 | $6,090,462 |
| M. Scott Harris, M.DChief Medical Officer | $497,952 | $541,952 | $1,228,016 | $189,222 | $3,563 | $2,460,705 |
| M. Scot Roberts, Ph.D.Chief Scientific Officer | $468,563 | $541,952 | $1,228,016 | $178,054 | $2,343 | $2,418,928 |
What changed and why
- 6,090,462 CEO total compensation in 2024 compared with 5,482,089 in 2023.
- 3,536,567 CEO option awards exceeded 1,560,896 in stock awards.
- 330,931 CEO non-equity incentive compensation was reported for 2024.
- 55%55% CEO annual discretionary incentive bonus opportunity is specified under the employment agreement.
- 28,708 CEO all other compensation included 5,785 of commuting expense.
- 40%40% and 30% annual bonus opportunities apply to the Chief Medical Officer and Chief Scientific Officer, respectively.
Other Altimmune proxy statements
- 2026 proxy statement
Vipin K. Garg, Ph.D. paid $8M (+32% on the year).
Filed Mar 17, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.